Treatment of AL amyloidosis with bendamustine: a study of 122 patients

Blood. 2018 Nov 1;132(18):1988-1991. doi: 10.1182/blood-2018-04-845396. Epub 2018 Aug 14.

Authors

Paolo Milani^{1

2}, Stefan Schönland³, Giampaolo Merlini^{1

2}, Christoph Kimmich³, Andrea Foli^{1

2}, Tobias Dittrich³, Marco Basset^{1

2}, Carsten Müller-Tidow³, Tilmann Bochtler³, Giovanni Palladini^{1

2}, Ute Hegenbart³

Affiliations

¹ Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
² Department of Molecular Medicine, University of Pavia, Pavia, Italy; and.
³ Department of Internal Medicine V, Hematology/Oncology/Rheumatology, Amyloidosis Center, University of Heidelberg, Heidelberg, Germany.

PMID: 30108065
DOI: 10.1182/blood-2018-04-845396

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antineoplastic Agents, Alkylating / therapeutic use*
Bendamustine Hydrochloride / therapeutic use*
Female
Humans
Immunoglobulin Light-chain Amyloidosis / drug therapy*
Male
Middle Aged
Prospective Studies
Treatment Outcome

Substances

Antineoplastic Agents, Alkylating
Bendamustine Hydrochloride

Grants and funding

MR/N006364/1/MRC_/Medical Research Council/United Kingdom